ESKATA (hydrogen peroxide) by Aclaris Therapeutics is 12. Approved for seborrheic keratosis. First approved in 2017.
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
ESKATA is a topical hydrogen peroxide solution approved for the treatment of seborrheic keratosis, a common benign skin growth. The mechanism of action is unknown, but hydrogen peroxide rapidly dissociates into water and reactive oxygen species upon application with no systemic absorption.
Product is in peak commercial lifecycle with minimal competitive pressure, suggesting stable mid-sized team operations focused on market penetration in dermatology.
12. CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The mechanism of action for ESKATA for the treatment of seborrheic keratosis is unknown. 12.2 Pharmacodynamics The pharmacodynamics of ESKATA in the treatment of seborrheic keratosis are unknown. 12.3 Pharmacokinetics Following application of…
KORTUC: Intra-tumoural Hydrogen Peroxide as a Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer in Terms of Toxicity and Tumour Response
Subjective Comfort With Multipurpose and Hydrogen Peroxide Lens Care Solutions in Soft Contact Lens Wearers
Worked on ESKATA at Aclaris Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moAclaris Therapeutics is hiring 1 role related to this product
ESKATA currently shows minimal job market activity with only one linked role in manufacturing, indicating a niche product with modest team headcount. Career opportunities are concentrated in supply chain and operations rather than commercial or medical affairs functions.
1 open roles linked to this drug